Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome-Reference-Cited by-同舟云学术

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome

Published:2014-05-29 Issue:22 Volume:123 Page:3414-3419
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Brioli Annamaria¹²,Giles Hannah³,Pawlyn Charlotte¹,Campbell John P.³,Kaiser Martin F.¹,Melchor Lorenzo¹,Jackson Graham H.⁴,Gregory Walter M.⁵,Owen Roger G.⁶,Child J. Anthony⁵,Davies Faith E.¹,Cavo Michele²,Drayson Mark T.³,Morgan Gareth J.¹

Affiliation:

1. Myeloma Research Centre, Division of Molecular Pathology, The Institute of Cancer Research, London, United Kingdom;

2. Istituto di Ematologia Seràgnoli, Università degli Studi di Bologna, Policlinico S. Orsola-Malpighi, Bologna, Italy;

3. Clinical Immunology Service, University of Birmingham Medical School, Birmingham, United Kingdom;

4. Haematology Department, University of Newcastle, Newcastle-upon-Tyne, United Kingdom;

5. Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom; and

6. St. James’s University Hospital, Leeds, United Kingdom

Abstract

Key Points The type of antibody secreted at relapse can serve as a marker of clonal heterogeneity. It is important to monitor for serum FLC in the suspicion of clinical relapse to ensure that FLC relapse is not missed.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/22/3414/1377350/3414.pdf

Reference27 articles.

1. Multiple myeloma.;Kyle;N Engl J Med,2004

2. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.;Walker;Blood,2012

3. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.;Walker;Leukemia,2014

4. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation.;Bladé;Br J Haematol,1998

5. Bence-Jones proteins and light chains of immunoglobulins (first of two parts).;Solomon;N Engl J Med,1976

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From Multiple Myeloma to Acute Myeloid Leukemia: A Case Report of a 61-year-old Woman after 8 Years of Chemotherapy and Immunotherapy;Recent Patents on Anti-Cancer Drug Discovery;2024-08

2. Performance Characteristics and Limitations of the Available Assays for the Detection and Quantitation of Monoclonal Free Light Chains and New Emerging Methodologies;Antibodies;2024-03-11

3. M-protein detection by mass spectrometry for minimal residual disease in multiple myeloma;Clinica Chimica Acta;2024-01

4. Laboratory and Clinical Settings of Heavy/Light Chain (HLC) Assays in the Management of Monoclonal Gammopathies and Multiple Myeloma;Journal of Personalized Medicine;2023-04-27

5. Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma;Leukemia & Lymphoma;2023-04-25